However, no studies to date have investigated the modulation of TNF antagonists targeting TNF-TNFR2 axis and their immunoregulation on breast cancer cells, while the potential of nanoparticles to mediate these effects in breast cancer is still unknown. This evidence concerns the gene TNFRSF1B and breast carcinoma.